Results 71 to 80 of about 34,322 (240)

Bowel ultrasound scan in the management of pediatric moderate ulcerative colitis: The applicability of international bowel ultrasound segmental activity score

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives To evaluate bowel ultrasound (BUS) findings and the diagnostic and prognostic performance of international bowel ultrasound segmental activity score (IBUS‐SAS) in children with moderate ulcerative colitis (UC), including its accuracy for assessing endoscopic activity and predicting clinical remission and colectomy within 12 months ...
Martina Di Benedetto, Luca Scarallo, Camilla Pannacci, Sara Renzo, Monica Paci, Sara Naldini, Jacopo Barp, Laura Tasciotti, Paolo Lionetti   +8 more
wiley   +1 more source

Update on the management of inflammatory bowel disease: specific role of adalimumab

Clinical and Experimental Gastroenterology, 2011
Luisa Guidi, Daniela Pugliese, Alessandro ArmuzziInternal Medicine and Gastroenterology, Complesso Integrato Columbus, Università Cattolica del Sacro Cuore, Rome, ItalyAbstract: Anti-tumor necrosis factor alpha (TNF-a) medications are a class ...
Guidi L, Pugliese D, Armuzzi A
doaj  

Abdominal pain in pediatric immunoglobulin A vasculitis: Risk factors and severity predictors in a multicenter cohort

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives To identify risk factors for abdominal pain and predictors of complicated abdominal pain in pediatric immunoglobulin A vasculitis (IgAV). Methods Retrospective multicenter study including children and adolescents (≤18 years) fulfilling the European League Against Rheumatism/Pediatric Rheumatology International Trials Organization ...
Francisco Hugo Rodrigues Gomes, Natalia Maronese, Leticia Lizardo Magalhaes, Davi Casale Aragon, Gleice Clemente, Maria Teresa Terreri, Claudio Arnaldo Len, Rozana Gasparello de Almeida, Marta Cristine Felix Rodrigues, Flavio Sztajnbok, Lia Vineyard Steuer, Matheus Santos França, Clovis Artur Almeida da Silva, Virginia Paes Leme Ferriani, Luciana Martins de Carvalho   +14 more
wiley   +1 more source

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience

JPGN Reports, EarlyView.
Abstract Objectives To evaluate the durability and predictors of loss of response of infliximab (IFX) over 2 years in paediatric Crohn's disease (CD) utilizing a proactive therapeutic drug monitoring (TDM) strategy. Methods A retrospective, single‐centre cohort study was conducted at The Children's Hospital at Westmead (CHW), Australia, from January ...
Cher Wei Chuah, Jessica Eldredge, Annabel Magoffin, Edward Vincent O'Loughlin, Calvin Joomann Park, Juliana Puppi, Susan Siew, Michael Stormon, Kunal Thacker, Shoma Dutt   +9 more
wiley   +1 more source

Pyoderma Gangrenosum in a Patient with Crohn’s Disease Treated with Adalimumab: A Case-Based Review and Systematic Review of the Current Literature

Clinics and Practice
Background: Pyoderma gangrenosum (PG) is a rare inflammatory cutaneous disorder that frequently occurs in association with systemic diseases such as inflammatory bowel disease (IBD).
Fotios S. Fousekis, Konstantinos Mpakogiannis, Emmanouil Karampinis, Ioanna Nefeli Mastorogianni, Dimitrios K. Christodoulou, Marina Papoutsaki, Evanthia Zampeli, Konstantinos H. Katsanos   +7 more
doaj   +1 more source

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Objectives Adalimumab biosimilars are as safe and effective compared to the originator. Adult patients with inflammatory bowel disease (IBD) who switched to a biosimilar have comparable outcomes, but pediatric data are limited. This study evaluates clinical outcomes of children and young adults with IBD following a nonmedical, insurance‐driven
Daniel Himelstein, Megan McNicol, Mahmoud Abdel‐Rasoul, Brendan M. Boyle, Hilary K. Michel, Ross Maltz   +5 more
wiley   +1 more source

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis

Pharmaceuticals
Background: Adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult rheumatoid arthritis (RA), and subsequently approved for pediatric treatment of various autoimmune diseases in children of different ages ...
Wenting Zhang, Ziqi Xu, Yamin Shu, Sainan Shu, Qilin Zhang   +4 more
doaj   +1 more source

Use of Patient Reported Outcome Measurements Information in Clinical Practice in Spain for the Clinical Management of Psoriasis Patients—Summer Project

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Routine collection of patient perspectives about psoriasis and its treatment through patient reported outcome measurements (PROMs), alongside clinician reported outcome measurements (CROMs), may improve clinical outcomes and facilitate shared decision making.
Jaime Notario, Jorge Magdaleno‐Tapial, Raquel Rivera, Josep Riera‐Monroig, Conrad Pujol, Cynthia Novella, Manuel Cuervas‐Mons, Pablo de la Cueva   +7 more
wiley   +1 more source

A British Pharmacological Society Position Statement on Medications in Pregnancy and Lactation

British Journal of Clinical Pharmacology, EarlyView.
Agnesa Mustafa, Cleodie C. Swire, Reya V. Shah, Bernadette Jenner, Rory H. McLean, Muhammad Shamsher Ahmed, Adrie Bekker, Julia Zöllner, Rachel K. Scott, Robert R. Bies, Sara K. Quinney, Dagan O. Lonsdale, Emma Forton Magavern, Catriona Waitt, Anita Banerjee   +14 more
wiley   +1 more source